My main scientific interests concern experimental and clinical issues of myeloproliferative disorders, that have represented the field of investigation since my doctoral thesis. I have been working on the molecular characterization of the gene expression profile in hematopoietic progenitors of patients with Primary myelofibrosis and I have more recently completed some observations concerning epigenetic mechanisms in MPD. I have been also involved in the study of a novel animal model of myelofibrosis, the GATA-1low mice. Current areas of research include preclinical studies on JAK-STAT pathway and PI3K/Akt/mTOR pathway as a therapeutic target in myeloproliferative neoplasms, coding and not-coding RNA expression profile, exome and RNA sequencing. Furthermore, I am strongly committed to clinical work, having in routine charge patients with MPNs and being involved in clinical protocols with novel drugs and in epidemiologic studies. Author of 111 publications on international scientific journals (ISI h-index=32, Total Impact Factors = 707.269, Mean IF = 13.601), chapters of Books and proceedings of international conferences.